# Drug-Induced AKI: Comprehensive Overview

## Clinical Summary

Drug-induced acute kidney injury (AKI) accounts for **20–30% of hospital-acquired AKI**^([1](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref1)),^([14](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref14)) and represents one of the most preventable causes of acute renal dysfunction in clinical practice. The wide spectrum of mechanisms—from hemodynamic changes to direct tubular toxicity to immune-mediated interstitial nephritis—requires systematic recognition and rapid intervention. This overview synthesizes mechanisms, high-risk agents, diagnostic approaches, and management strategies for clinicians managing complex patients on multiple nephrotoxic medications.

------------------------------------------------------------------------

## 1. EPIDEMIOLOGY

### Incidence and Prevalence

- **Hospital-wide:** 20–30% of all AKI cases are drug-related
- **ICU population:** 35–50% of ICU AKI has medication contribution
- **Ambulatory CKD:** 5–10% experience drug-induced GFR decline annually
- **Polypharmacy patients (≥5 drugs):** 2–3× higher risk of drug-induced AKI

### High-Risk Populations

| Population | Relative Risk | Key Factors |
|----|----|----|
| CKD stage 3b–5 | 5–10× | Reduced renal mass, drug accumulation |
| Diabetes mellitus | 3–5× | Hemodynamic fragility, microalbuminuria marker of vascular disease |
| Volume depletion | 4–8× | Decreased renal perfusion pressure dependency |
| Age ≥65 years | 2–3× | Reduced GFR, polypharmacy, frailty |
| Heart failure | 3–5× | Neurohormonal activation, diuretic sensitivity |
| Hepatic cirrhosis | 4–6× | Hemodynamic instability, protein synthesis dysfunction |
| Sepsis/fever | 2–4× | Volume redistribution, hypotension |

### Polypharmacy Syndrome

The risk amplifies non-additively with drug combinations. Classic example: **triple whammy** (NSAID + ACEi/ARB + diuretic) increases AKI risk \>10-fold in elderly patients with CKD.^([6](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref6))

------------------------------------------------------------------------

## 2. MECHANISMS OF DRUG-INDUCED KIDNEY INJURY

Drug nephrotoxicity operates through distinct histopathologic and functional pathways. Understanding mechanism is essential for risk stratification, prevention, and management decisions.

### Mechanism Classification and Examples

| **Mechanism** | **Histology** | **Key Agents** | **Timeline** | **Reversibility** |
|----|----|----|----|----|
| **Pre-renal (hemodynamic)** | Normal glomeruli, preserved tubules | NSAIDs, ACEi/ARB, calcineurin inhibitors, iodinated contrast | Acute (24–72 h) | Usually yes (48–96 h) |
| **Acute tubular necrosis (ATN)** | Epithelial cell sloughing, debris | Aminoglycosides, cisplatin, amphotericin B, tenofovir | 3–7 days | Partial to variable |
| **Acute interstitial nephritis (AIN)** | Interstitial inflammation, T-cell infiltrate | Beta-lactams (nafcillin \>others), PPIs, NSAIDs, checkpoint inhibitors, 5-ASA | 3–14 days (acute); weeks (delayed) | ~90% with drug withdrawal |
| **Crystal nephropathy** | Intratubular crystals, tubular obstruction | IV acyclovir, methotrexate, indinavir, sulfadiazine | Acute during/post infusion | Rapid with hydration |
| **Osmotic nephropathy** | ATN-like, without crystals or inflammation | IV immunoglobulin (IVIG), hypertonic mannitol, hydroxyethyl starch (HES) | Acute (12–48 h) | Yes, with hydration |
| **Thrombotic microangiopathy (TMA)** | Endothelial injury, microvascular thrombi | Calcineurin inhibitors (high-dose), gemcitabine, VEGF inhibitors, sirolimus | Days to weeks | Partial; often irreversible |
| **Glomerulonephritis** | GN pattern on biopsy (ANCA, MCD, others) | NSAIDs (membranous, MCD), gold, penicillamine, hydralazine, checkpoint inhibitors | Weeks to months | Variable; some ANCA-ANCA AKI needs immunosuppression |

NSAID Paradox: NSAIDs cause both hemodynamic pre-renal AKI AND true AIN with glomerulonephritis (MCD pattern). Distinguish by clinical context and biopsy.

------------------------------------------------------------------------

## 3. HEMODYNAMIC AGENTS (PRE-RENAL PATTERN)

### NSAIDs: Prostaglandin-Dependent GFR

**Mechanism:** NSAIDs inhibit renal prostaglandin (PGE2, PGI2) synthesis^([2](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref2)) , which are major efferent arteriolar dilators and maintain GFR in patients with: - Effective circulating volume depletion (CHF, cirrhosis, nephrotic syndrome) - Renal artery disease - Baseline CKD

**Risk Factors for NSAID AKI:** - CKD stage ≥3 (eGFR \<60) - Age \>65 years - Diabetes mellitus - Concurrent ACEi/ARB (disrupts efferent arteriolar tone compensation) - Concurrent diuretics (hypovolemia) - **Triple whammy:** NSAID + ACEi/ARB + diuretic = **\>10-fold AKI risk**

**COX-2 Selectivity Does NOT Protect the Kidney** — Both selective COX-2 inhibitors (celecoxib) and non-selective NSAIDs (ibuprofen, naproxen) carry identical nephrotoxicity risk in susceptible patients. The “selective COX-2” hypothesis failed in renal outcomes trials.

**Clinical Pearl:** Expect transient creatinine rise of 20–30% after starting NSAID in CKD patients; \>30% rise warrants reassessment.

**References:** See comprehensive nsaid ckd report and nsaid nephropathy review for detailed pharmacokinetics and case examples.

------------------------------------------------------------------------

### ACEi/ARBs: Efferent Arteriolar Dilation

**Mechanism:** ACEi/ARBs dilate the efferent arteriole preferentially by blocking angiotensin II–mediated vasoconstriction. This **lowers glomerular capillary hydrostatic pressure** and reduces single-nephron GFR.

**Predictable Creatinine Rise:** - Expect 15–30% increase in serum creatinine within 2–4 weeks - \>30% rise suggests bilateral renal artery stenosis, cardiorenal syndrome, or volume depletion - Cystatin C may rise less than creatinine (volume effect)

**When to Hold vs. Continue:** - **Continue** if creatinine rise \<30% and patient has CKD, proteinuria, or hypertension (renoprotective benefit outweighs risk) - **Hold** if creatinine rise \>30%, hemodynamically unstable, or suspected RAS - **Recheck creatinine** 1–2 weeks after initiation; stabilization on new baseline is normal

**Bilateral RAS:** High-risk scenario — GFR depends on efferent arteriolar tone maintained by angiotensin II. ACEi/ARB can cause acute, severe GFR collapse.

**References:** prerenal aki volume assessment review

------------------------------------------------------------------------

### Calcineurin Inhibitors (Tacrolimus, Cyclosporine)

**Mechanism:**^([7](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref7)) Afferent arteriolar vasoconstriction via: - Reduced prostaglandin and nitric oxide production - Increased sympathetic activity and local renin-angiotensin activation - At supratherapeutic levels: thrombotic microangiopathy (TMA) with hemolysis

**Dose-Dependent Nephrotoxicity:** - Therapeutic tacrolimus trough (5–15 ng/mL in most settings) → mild GFR reduction - Supratherapeutic tacrolimus (\>15 ng/mL) → risk of acute AKI and/or TMA - Chronic calcineurin inhibitor use → chronic kidney disease in 20–30%

**Management:** - Monitor trough levels religiously; adjust dose to target range - Baseline GFR assessment mandatory before initiation - Concurrent NSAIDs contraindicated - May combine with other agents targeting different pathways (mycophenolate, mammalian target of rapamycin inhibitors)

------------------------------------------------------------------------

## 4. DIRECT TUBULAR TOXICITY

### Aminoglycosides (Gentamicin, Tobramycin, Amikacin)

**Mechanism:** 1. Glomerular filtration of positively charged aminoglycosides 2. Uptake via **megalin receptor** on proximal tubule brush border^([8](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref8)) 3. Lysosomal accumulation in proximal tubule S1–S3 segments 4. Generation of reactive oxygen species (ROS) → mitochondrial dysfunction → cell death

**Classic AKI Pattern:** - **Non-oliguric AKI** (\>400 mL/24 h urine despite ↑Cr) - **Reversible** if caught early; delayed ototoxicity risk even with AKI resolution - Urinary casts and tubular epithelial cells on urinalysis

**Risk Factors:** - Duration of therapy \>7 days (dose-cumulative) - Trough levels \>5 ng/mL (target \<1–2 ng/mL for synergy) - Pre-existing CKD (eGFR \<60) - Dehydration, sepsis, liver disease - Concurrent nephrotoxins (NSAIDs, contrast, amphotericin B)

**Prevention & Monitoring:** - **Extended-interval dosing** (q24 h or q36 h) preferred over conventional q8 h for improved safety - Baseline and periodic serum creatinine, trough levels, urinalysis - Limit duration to ≤7 days when possible - Adequate hydration

**References:** antibiotic aki report, gentamicin aki timeline

------------------------------------------------------------------------

### Other Antibiotic Nephrotoxins

**Vancomycin:** - Mechanism: Direct tubular toxicity + cast nephropathy at high trough levels - At-risk concentrations: Trough \>15–20 μg/mL - Risk factors: CKD, dehydration, concurrent aminoglycosides - Management: Target vancomycin trough 15–20 μg/mL (lower end if eGFR \<30)

**Daptomycin:** - Mechanism: Unclear; possible myosin heavy chain cross-reactivity leading to CK elevation - Presentation: Marked CK rise (\>2000 U/L common), AKI in 5–10% of treated patients - Risk factors: Higher doses (\>6 mg/kg), CKD, concurrent statin use - Management: Baseline and weekly CK monitoring; hold if CK \>1000 U/L - **Reference:** daptomycin aki review

**Polymyxins (Polymyxin B, Colistin):** - Mechanism: Dual toxicity — proximal tubule (ATN) + distal tubule (voltage-dependent blockade) - Used for extensively drug-resistant Gram-negative organisms - Risk: 50–60% experience AKI during therapy - Management: Dose adjustment in renal impairment; monitor Cr q48 h

**Nafcillin (and other Beta-lactams):** - Mechanism: Primarily AIN, less commonly ATN - Timeline: 3–7 days after initiation (can be delayed 1–2 weeks) - Risk factors: Prolonged infusion schedules, high cumulative doses, renal impairment - **Reference:** nafcillin aki timeline

------------------------------------------------------------------------

### Contrast-Induced AKI

**Epidemiology (Evolving):** - Traditional estimates: 10–15% AKI risk in high-risk patients - Modern trials (PRESERVE^([3](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref3)) 2018, AMACING^([4](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref4)) 2017): **True incidence 2–3%** in most populations, largely volume-related - Osmolality hypothesis less relevant with modern iso-osmolar and low-osmolar contrast agents

**Risk Stratification:** \| Risk Category \| Baseline eGFR \| Criteria \| Adjusted Risk \| \|:—\|:—\|:—\|:—\| \| High risk \| \<30 \| Diabetes, CHF, advanced CKD \| 5–10% \| \| Intermediate \| 30–60 \| Diabetes OR age \>70 OR CHF \| 2–5% \| \| Low risk \| \>60 \| No comorbidities \| \<1% \|

**Prevention (Evidence-Based):** 1. **Isotonic (0.9%) saline hydration:** 500–1000 mL pre-procedure, 100–150 mL/h during and 4–6 hours post-procedure 2. **Minimize contrast volume:** Use \<3:1 ratio (mL contrast : patient weight in kg) 3. **Discontinue metformin** if eGFR \<30 (48 hours post-procedure) 4. **Discontinue NSAIDs** 48 hours pre-procedure 5. **Hold diuretics** if possible; resume after adequate hydration

**Unproven/Ineffective Interventions:** - **NAC (N-acetylcysteine):** ACT trial^([5](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref5)) (2011) showed no benefit; not recommended - Hyperbaric oxygen, statins, theophylline, dopamine: No evidence

**Management of Suspected Contrast-Induced AKI:** - Monitor creatinine at 48–72 hours post-procedure - Ensure continued hydration - Hold nephrotoxins (NSAIDs, diuretics, metformin) - Most cases resolve within 5–7 days if managed supportively

------------------------------------------------------------------------

## 5. ACUTE INTERSTITIAL NEPHRITIS (AIN)

**Definition:** Immune-mediated tubulointerstitial inflammation, drug-induced in ~80% of cases^([1](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref1)) .

**Classic Triad (Present in \<10% of Cases):** - Rash (urticarial, maculopapular) - Fever - Eosinophilia (≥1500/μL, ≥5% differential)

Absence of classic triad does NOT exclude AIN. Most AIN cases present with AKI and pyuria without systemic features.

**Most Common Drug Causes (Modern):** 1. **Proton-pump inhibitors (PPIs)** — now \#1 cause in many centers (\>30% of AIN cases)^([11](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref11)) 2. Beta-lactam antibiotics (penicillins, cephalosporins) — peak onset 3–7 days 3. NSAIDs (glomerular and tubulointerstitial patterns) 4. Immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4) 5. 5-aminosalicylates (mesalamine, sulfasalazine) 6. Quinolones, sulfonamides, allopurinol

**Diagnostic Approach:** - **UA:** Pyuria (sterile), eosinophiluria (Wright-Giemsa stain), proteinuria (usually \<1 g/day) - **Serum creatinine:** Typically rises over 3–14 days; can be fulminant - **Imaging:** Renal ultrasound unremarkable or mild echogenicity increase - **Kidney biopsy:** Gold standard — shows interstitial edema, mononuclear cell infiltrate (predominantly T cells), preserved glomeruli

**Management:** 1. **Discontinue inciting drug immediately** — most important intervention 2. **Hold NSAIDs** if taking concurrently 3. **Supportive care:** Hydration, electrolyte monitoring 4. **Corticosteroids:** Consider if: - Biopsy-proven AIN - Oliguria or rapid Cr rise (\>0.5 mg/dL/day) - Delay \>14 days before drug withdrawal (prednisone 1 mg/kg × 4–6 weeks, then taper) 5. **Monitor creatinine:** Recovery often delayed 1–3 months even after drug withdrawal

PPI-Induced AIN: Risk increases with duration of therapy; occurs even at standard doses. Consider deprescribing in patients with unexplained AKI on chronic PPI therapy.

**References:** acute interstitial nephritis review, B2M AIN Comprehensive Review, ppi kidney report

------------------------------------------------------------------------

## 6. CRYSTAL NEPHROPATHY

**Mechanism:** Drug precipitation in tubular fluid, causing obstructive AKI. Prevention is critical — treatment cannot “dissolve” existing crystals.

### IV Acyclovir

- **Risk setting:** IV bolus infusion in dehydrated patients
- **Crystal type:** Monohydrate crystals in distal tubules
- **Prevention:** Adjust acyclovir to kidney function, infuse over at least 1 hour, and ensure adequate hydration matched to volume status; avoid a fixed high infusion-fluid rate in every patient. [Acyclovir prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69a98000-adef-4323-89a7-09e035a257d4).
- **Management:** Stop infusion, hydrate, monitor Cr (most improve within 48–96 h)

### Methotrexate

- **Risk:** High-dose (≥1 g/m²) IV or intraarterial injection in patients with renal impairment
- **pH-dependent:** Crystal precipitation increases at lower urine pH
- **Prevention:** For high-dose methotrexate, assess kidney function and eligibility under the specific oncology regimen. Use protocolized hydration and urine alkalinization (generally urine pH at least 7), monitor methotrexate concentrations and kidney function, and provide leucovorin rescue; urgently assess delayed clearance for rescue measures such as glucarpidase. [Crystalline nephropathy review](https://pmc.ncbi.nlm.nih.gov/articles/PMC8640557/).
- **Management:** High-dose leucovorin rescue per protocol; aggressive hydration; hemodialysis if severe AKI

### Indinavir (Protease Inhibitor)

- **Risk:** Dehydration, concurrent nephrotoxins
- **Prevention:** Ensure adequate hydration (\>48 oz fluid/day)
- **Management:** Hydration, crystal clearance over days

### Sulfadiazine

- **Risk:** Trimethoprim-sulfamethoxazole and sulfadiazine (sulfadiazine more common)
- **Prevention:** Hydration + urinary alkalinization (similar to methotrexate)

------------------------------------------------------------------------

## 7. OSMOTIC NEPHROPATHY

**Mechanism:** Hyperosmolar solution drawn into tubular fluid → cell swelling, tubular obstruction, rhabdomyolysis without myoglobinuria visible.

### IV Immunoglobulin (IVIG)

- **Risk:** Sucrose-containing formulations (less common now; alternative formulations available)
- **AKI incidence:** 2–10% in at-risk populations
- **Risk factors:** CKD, diabetes, dehydration, concurrent diuretics, age \>60
- **Prevention:** Adequate hydration before and after infusion; use glucose/maltose-based formulations if available
- **Management:** Hydration, diuretics if fluid-overloaded

### Mannitol

- **Risk:** Hypertonic mannitol (20% solution) used for cerebral edema, raised intracranial pressure
- **Risk factors:** CKD, sepsis, rhabdomyolysis, loop diuretic co-use
- **Prevention:** Baseline osmolality and Cr; limit duration
- **Monitor:** Osmolar gap; stop if serum osmolarity \>320 mOsm/kg

### Hydroxyethyl Starch (HES)

- **Regulatory status:** Contraindicated in many countries (EU, Australia) for sepsis resuscitation
- **Mechanism:** Oncotic pull + direct tubular toxicity
- **AKI risk:** 1–5% even with standard dosing in sepsis
- **Recommendation:** Use crystalloid (normal saline or balanced crystalloid) instead

------------------------------------------------------------------------

## 8. THROMBOTIC MICROANGIOPATHY (TMA)

**Mechanism:** Drug-induced endothelial injury → complement activation, platelet consumption, microangiopathic hemolytic anemia (MAHA), thrombocytopenia, AKI.

### Calcineurin Inhibitors (High-Dose)

- **Supratherapeutic tacrolimus or cyclosporine** (trough \>15 ng/mL)
- Mechanism: Direct endothelial toxicity, C5b-9 complement deposition
- **Clinical features:** AKI + schistocytes + thrombocytopenia + hemolysis
- **Management:** Immediate dose reduction; consider alternative immunosuppression

### Gemcitabine

- **Chemotherapy agent for lymphoma, pancreatic cancer, ovarian cancer**
- **Incidence:** 0.5–1% of treated patients
- **Onset:** Often delayed, weeks to months after exposure
- **Features:** Microangiopathic hemolytic anemia, thrombocytopenia, AKI, hypertension
- **Management:** Discontinue drug; plasma exchange if MAHA prominent; monitor Cr

### VEGF Inhibitors (Anti-Angiogenic Tyrosine Kinase Inhibitors)

- **Agents:** Sunitinib, sorafenib, bevacizumab, axitinib, others
- **Mechanism:** Off-target ADAMTS13 inhibition, complement-mediated endothelial injury
- **Incidence:** 5–15% develop hypertension; 1–2% develop TMA
- **Management:** Dose reduction; blood pressure control; consider drug discontinuation if TMA features present

------------------------------------------------------------------------

## 9. DRUG-INDUCED GLOMERULONEPHRITIS

### NSAIDs

- **Glomerular pattern:** Minimal change disease (MCD), membranous nephropathy, occasionally IgA
- **Presentation:** Nephrotic syndrome, AKI
- **Timeline:** Weeks to months of NSAID exposure
- **Mechanism:** Direct immune complex formation, podocyte toxicity
- **Management:** NSAID discontinuation + corticosteroids if biopsy-proven

### Gold (Chrysotherapy)

- **Pattern:** Membranous nephropathy most common
- **Incidence:** 1–3% of treated patients
- **Management:** Discontinue; monitor proteinuria; consider immunosuppression if nephrotic

### Penicillamine

- **Patterns:** Membranous, MCD, ANCA-ANCA vasculitis (rare)
- **Incidence:** 1–7%
- **Management:** Discontinue immediately if ANCA-positive; immunosuppression needed

### Hydralazine

- **Pattern:** ANCA-ANCA vasculitis (anti-MPO predominant)
- **Risk factors:** Dose \>200 mg/day, female, HLA-DR4 positive
- **Management:** Discontinue; cyclophosphamide + corticosteroids if rapidly progressive

### Checkpoint Inhibitors

- **Patterns:** Glomerulonephritis (ANCA, membranous, others), AIN, TMA^([9](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref9)),^([10](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref10))
- **Presentation:** 1–3 months post-initiation; presents as AKI ± proteinuria/hematuria
- **Management:** Early recognition mandatory; often requires immunosuppression (corticosteroids ± cyclophosphamide)
- **References:** ici kidney injury diagnosis pathology review

------------------------------------------------------------------------

## 10. OTHER DRUG-INDUCED INJURY PATTERNS

### Rhabdomyolysis-Associated AKI

**Common Triggers:** - **Statins:** Myositis, rhabdomyolysis (rare; \<1:10,000 patients) - **Daptomycin:** CK rise in 5–10% - **Corticosteroids:** High-dose IV pulse therapy - **Alcohol + other drugs:** Synergistic risk

**Presentation:** Elevated CK (usually \>1000 U/L), myoglobinuria (cola-colored urine), AKI, hyperkalemia, hyperphosphatemia, hypocalcemia.

**Management:** Stop the inciting drug and assess the precipitant, perfusion, volume status, potassium/ECG, and kidney function. Give isotonic crystalloid when resuscitation is indicated, titrating to response and congestion rather than a fixed high rate or forced urine-output goal. Routine bicarbonate or mannitol is not recommended for rhabdomyolysis-associated AKI prevention. Follow CK until it reliably falls, and monitor electrolytes/creatinine more frequently when unstable. Use KRT for refractory hyperkalemia, severe acidemia, pulmonary edema, or uremic complications, not CK elevation or AKI stage alone. [AAST consensus](https://tsaco.bmj.com/content/7/1/e000836).

**References:** rhabdo comprehensive guide, Rhanbdo HMGCR antibody nephrology consultation

------------------------------------------------------------------------

### Methylene Blue–Induced Nephrotoxicity

- **Use:** Intra-operative visualization, serotonin syndrome treatment
- **Mechanism:** Direct tubular toxicity; oxidative stress
- **Risk factors:** High doses, CKD, dehydration
- **Management:** Hydration, avoid in CKD
- **References:** comprehensive methylene blue nephrotoxicity

### Platinum Chemotherapy Agents

- **Agents:** Cisplatin (most nephrotoxic), carboplatin, oxaliplatin
- **Mechanism:** Direct proximal tubule toxicity; glomerular effects less common^([12](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html#ref12))
- **Incidence:** 10–35% with single dose; cumulative with repeated cycles
- **Risk factors:** High cumulative dose, CKD, aminoglycosides, NSAIDs, dehydration
- **Prevention:** Vigorous hydration; consider amifostine (cytoprotective agent) for cisplatin
- **Management:** Monitor Mg, K, phosphate (Fanconi-like tubular dysfunction); dialysis if severe
- **Reference:** platinum nephrotoxicity review

------------------------------------------------------------------------

## 11. DIAGNOSTIC APPROACH TO SUSPECTED DRUG-INDUCED AKI

### Timeline Integration

**Temporal relationship between drug exposure and AKI onset strongly suggests causation:**

| **Drug Class** | **Typical Onset** | **Pattern** |
|----|----|----|
| Contrast, NSAIDs, ACEi, diuretics | 24–72 h | Pre-renal, usually reversible |
| Aminoglycosides | 3–7 days | Non-oliguric ATN |
| Beta-lactams (AIN) | 3–14 days | AKI + pyuria + eosinophiluria |
| Platinum agents | Acute to delayed | ATN → CKD evolution |
| Methotrexate, acyclovir | Hours to 24 h | Crystal nephropathy |

### Urinalysis Interpretation by Mechanism

| **Mechanism** | **Urinary Findings** |
|----|----|
| **Pre-renal** | Bland; FENa \<1% (unless diuretics co-used) |
| **ATN** | Muddy brown casts, tubular epithelial cells, granular casts, FENa \>2% |
| **AIN** | Pyuria (WBC casts), eosinophiluria (Wright-Giemsa), mild proteinuria |
| **Crystal nephropathy** | Crystals (may not be visible on routine; requires specialized staining) |
| **Glomerulonephritis** | Hematuria, RBC casts, proteinuria (≥2 g/day) |
| **TMA** | Schistocytes on blood smear (not urine); hematuria, proteinuria |

### Kidney Biopsy Indications

**Consider biopsy if:** - AKI persists \>2–3 weeks despite drug discontinuation - Clinical presentation atypical (rapidly progressive GN, nephrotic-range proteinuria) - Need to confirm AIN before committing to corticosteroid therapy - Differentiation between AIN and pre-renal AKI critical for management

**Biopsy findings guide therapy:** AIN may benefit from corticosteroids; pre-renal does not.

------------------------------------------------------------------------

## 12. MANAGEMENT PRINCIPLES

### Tier-1: Drug Discontinuation

- **Most critical intervention** — the only intervention addressing the underlying cause
- Often leads to full renal recovery if done early
- Delayed recognition and continued drug exposure → worse outcomes and chronic kidney disease risk

### Tier-2: Supportive Care

1.  **Fluid:** Correct demonstrated volume depletion with isotonic crystalloid and reassess perfusion, urine output, and congestion. Do not apply a high urine-output target to every drug-induced AKI or continue fluid escalation in anuria.
2.  **Electrolyte management:** Monitor K, Mg, phosphate, calcium; supplement as needed
3.  **Avoid exacerbating drugs:** Hold NSAIDs, diuretics (unless CHF), additional nephrotoxins
4.  **Kidney replacement therapy:** Escalate for refractory hyperkalemia, severe acidemia, pulmonary edema, or uremic complications; oliguria alone is a warning requiring reassessment, not an automatic trigger.

### Tier-3: Mechanism-Specific Therapy

- **AIN:** Corticosteroids if biopsy-proven or high clinical suspicion with oliguria
- **Crystal nephropathy:** Use drug-specific prevention. High-dose methotrexate requires protocolized hydration, urine alkalinization, drug-level monitoring, and rescue therapy. Acyclovir prevention uses renal dosing, slow infusion, and adequate hydration; routine urine alkalinization is not established for acyclovir.
- **Rhabdomyolysis:** Treat the precipitant and use volume-guided crystalloid when indicated; no routine bicarbonate or mannitol for AKI prevention.
- **TMA:** Plasma exchange if MAHA prominent; drug discontinuation

### Tier-4: Monitoring and Follow-Up

- **Baseline assessment:** Serum creatinine at 48–72 h post-procedure/drug initiation
- **Serial Cr:** Every 1–2 days during acute phase; weekly if stable
- **Cystatin C:** Useful to differentiate volume effects from true GFR decline in early stages
- **Recovery trajectory:** Most drug-induced AKI recovers within 7–14 days; AIN recovery can be delayed 1–3 months
- **Chronic CKD risk:** Some medications (platinum agents, calcineurin inhibitors) carry cumulative CKD risk requiring long-term follow-up

Rechallenge Decision: Before re-introducing a drug after suspected drug-induced AKI, confirm: 1. Complete renal recovery to baseline (if possible; at least stable for 1–2 weeks) 2. No alternative agents available 3. Clear clinical indication 4. Plan for intensive monitoring (baseline Cr, repeat Cr 48–72 h, weekly × 4 weeks) 5. Patient counseling on warning signs (oliguria, edema, weight gain)

------------------------------------------------------------------------

## 13. PREVENTION IN HIGH-RISK PATIENTS

### Pre-Medication Assessment

- **Calculate baseline eGFR** (CKD-EPI preferred; use cystatin C if creatinine unreliable)
- **Assess volume status:** Euvolemia required before nephrotoxic drugs
- **Screen for concurrent nephrotoxins:** NSAID + ACEi/ARB + diuretic = contraindicated
- **Review medication list** for drug-drug interactions that amplify nephrotoxicity

### Pre-Procedure (Contrast, Surgery)

- **Minimum eGFR:** Many institutions require eGFR ≥30 before elective procedures
- **Hydration:** Start 24 h before if possible (500 mL × 2 pre-procedure)
- **Discontinue:** Metformin (if eGFR \<45–60), NSAIDs (48 h before), diuretics (48 h before)
- **Administer:** Isotonic hydration during and 4–6 h post-procedure

### Pre-Medication (Aminoglycosides, Amphotericin, Cisplatin)

- **Extended-interval aminoglycoside dosing** preferred (q24 h vs. q8 h)
- **Amphotericin B:** Liposomal formulation preferred; slower infusion
- **Cisplatin:** Hypertonic saline pre- and post-hydration; amifostine consideration
- **Baseline Cr + repeat 48–72 h**

------------------------------------------------------------------------

## 14. RELATIVE CONTRAINDICATIONS IN CKD

**Avoid or use with extreme caution in CKD stage 3b–5 (eGFR \<45):**

| **Drug** | **CKD Stage** | **Alternative or Modification** |
|----|----|----|
| **NSAIDs** | Any CKD | Acetaminophen, tramadol, opioids |
| **ACEi/ARB alone** | All (but benefit usually outweighs risk) | Monitor Cr carefully; hold if Cr ↑ \>30% |
| **Diuretics + ACEi/ARB** | Stage ≥3b | Deprescribe one agent if possible |
| **Metformin** | eGFR \<30 (or \<45 if age \>65) | GLP-1 agonist, SGLT2i, DPP-4i, insulin |
| **SGLT2 inhibitors** | eGFR \<20 | Yes, but use with caution; monitor volume status |
| **NSAIDs + ACEi + diuretic** | Any | **CONTRAINDICATED** — redesign regimen |
| **IV contrast (high volume)** | eGFR \<30 | Hydration mandatory; consider MRI alternative |
| **Aminoglycosides** | eGFR \<60 | Extended-interval dosing; more frequent monitoring |
| **Amphotericin B** | All | Liposomal \> conventional; monitor Cr |
| **Calcineurin inhibitors** | All | Necessary in transplant/immunosuppression; intensive monitoring |

------------------------------------------------------------------------

## 15. DRUG INTERACTIONS AMPLIFYING NEPHROTOXICITY

### “Triple Whammy” Variants

| **Combination** | **Mechanism** | **AKI Risk** | **Management** |
|----|----|----|----|
| NSAID + ACEi + Diuretic | Combined hemodynamic insult | **10–15×** | Avoid; reduce volume-depletion triggers |
| Aminoglycoside + Loop diuretic + NSAID | Volume depletion + direct toxicity | **5–8×** | Use extended-interval aminoglycosides; hydrate |
| Cisplatin + Aminoglycoside | Synergistic tubular toxicity | **8–10×** | Sequential administration if both necessary; TDM |
| Calcineurin inhibitor + NSAID | Hemodynamic + direct toxicity | **6–8×** | Avoid NSAIDs; use acetaminophen |
| Metformin + IV Contrast | Metformin accumulation in renal failure | 2–3× (if AKI occurs) | Hold metformin 48 h post-contrast; recheck Cr |

------------------------------------------------------------------------

## 16. PATIENT COUNSELING

Discuss with patients on chronic nephrotoxic medications:

1.  **Avoid dehydration:** Maintain fluid intake; seek care for GI losses (diarrhea, vomiting)
2.  **Avoid NSAIDs:** Do not self-medicate with ibuprofen, naproxen; use acetaminophen instead
3.  **Monitor weight:** Report weight gain \>2–3 lbs in 1 week (edema/fluid retention sign)
4.  **Warning signs:** Oliguria (\<300 mL urine/day), dark urine, fatigue, shortness of breath
5.  **Medication adherence:** Do NOT miss doses of essential medications (ACEi, beta-blockers) out of fear
6.  **Follow-up labs:** Keep appointments for creatinine monitoring

------------------------------------------------------------------------

## 17. RELATED RESOURCES

### Drug-Induced AKI Deep-Dives (In-Vault)

- comprehensive nsaid ckd report — NSAID nephrotoxicity mechanisms and management
- antibiotic aki report — Detailed antibiotic nephrotoxicity
- gentamicin aki timeline — Aminoglycoside AKI progression and monitoring
- daptomycin aki review — Daptomycin-associated CK elevation and AKI
- nafcillin aki timeline — Beta-lactam AIN timeline and presentation
- ppi kidney report — PPI-induced AIN epidemiology and diagnosis

### AKI Classification & Staging

- aki staging classification review — KDIGO staging (stage 1–3)
- acute tubular necrosis review — ATN histology and physiology
- acute interstitial nephritis review — AIN etiology, diagnosis, management
- B2M AIN Comprehensive Review — Beta-2 microglobulin and AIN biomarkers
- prerenal aki volume assessment review — Pre-renal physiology and FENa interpretation

### Specialized Drug Toxicity

- rhabdo comprehensive guide — Rhabdomyolysis-induced AKI
- Rhanbdo HMGCR antibody nephrology consultation — Statin-induced myositis consultation
- comprehensive methylene blue nephrotoxicity — Methylene blue toxicity
- ici kidney injury diagnosis pathology review — Checkpoint inhibitor nephrotoxicity
- platinum nephrotoxicity review — Cisplatin and carboplatin renal effects
- vegf tki nephrotoxicity review — VEGF inhibitor renal complications

### Diagnostic & Management Frameworks

- aki workup summary — Systematic AKI diagnostic approach
- Biomarkers for Early Detection of AKI — NGAL, KIM-1, IL-18 in early AKI
- Hemodynamic Targets in AKI Literature Review — Resuscitation and perfusion goals

### Master Hub

- AKI Hub — Central navigation for all AKI-related content

------------------------------------------------------------------------

## SUMMARY & CLINICAL PEARLS

Key Takeaway: Drug-induced AKI is preventable and often reversible if recognized and managed early. Drug discontinuation is the cornerstone of treatment; supportive care addresses complications.

1.  **Risk stratification matters:** CKD + diabetes + age + volume depletion = high-risk patient; avoid nephrotoxic polypharmacy combinations.

2.  **Timeline is diagnostic:** Pre-renal AKI within 24–72 h of drug start; AIN at 3–14 days; contrast AKI within 48 h.

3.  **Urinalysis guides mechanism:** Muddy brown casts = ATN; pyuria + eosinophiluria = AIN; bland urine = pre-renal.

4.  **Triple whammy is real:** NSAID + ACEi + diuretic increases AKI risk \>10-fold in elderly CKD patients; avoid or monitor intensively.

5.  **Expect creatinine rise on ACEi/ARB:** 15–30% rise is expected; \>30% suggests RAS or cardiorenal syndrome.

6.  **PPI-induced AIN is common:** Consider deprescribing in patients with unexplained AKI on chronic PPIs.

7.  **Corticosteroids for AIN:** Only if biopsy-proven or high clinical suspicion with oliguria; not for pre-renal or ATN.

8.  **Recovery timeline:** Most drug-induced AKI resolves 7–14 days; AIN may take 1–3 months; platinum agents have chronic CKD risk.

9.  **Monitoring is essential:** Serial creatinine, urinalysis, electrolytes for all patients on nephrotoxic medications.

10. **Rechallenge carefully:** Only after complete renal recovery; requires informed consent and intensive follow-up.

------------------------------------------------------------------------

### Sources

1.  Perazella MA, Rosner MH. Drug-Induced Acute Kidney Injury. *Clin J Am Soc Nephrol*. 2022;17(8):1220–1233. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35273009/)
2.  Perazella MA. Pharmacology behind Common Drug Nephrotoxicities. *Clin J Am Soc Nephrol*. 2018;13(12):1897–1908. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29622670/)
3.  Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine (PRESERVE). *N Engl J Med*. 2018;378(7):603–614. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29130810/)
4.  Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. *Lancet*. 2017;389(10076):1312–1322. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28233565/)
5.  ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). *Circulation*. 2011;124(11):1250–1259. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21859972/)
6.  Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. *BMJ*. 2013;346:e8525. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23299844/)
7.  Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. *Clin J Am Soc Nephrol*. 2009;4(2):481–508. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19218475/)
8.  Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. *Kidney Int*. 2011;79(1):33–45. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20861826/)
9.  Cortazar FB, Kitchlu A, Strohbehn IA, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. *J Am Soc Nephrol*. 2020;31(2):435–446. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31896554/)
10. Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. *Kidney Int*. 2016;90(3):638–647. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27282937/)
11. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. *J Am Soc Nephrol*. 2016;27(10):3153–3163. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27080976/)
12. Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. *J Nephrol*. 2018;31(1):15–25. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28382507/)
13. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract*. 2012;120(4):c179–c184. [PubMed](https://pubmed.ncbi.nlm.nih.gov/22890468/)
14. Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. *Am J Med Sci*. 2003;325(6):349–362. [PubMed](https://pubmed.ncbi.nlm.nih.gov/12811231/)

------------------------------------------------------------------------

*Last reviewed and updated: 2026-02-28 by Clinical Nephrology Education Team. For questions or additions, contact medical director.*

### Also on this topic

The same subject at other levels of depth.

- **Student handout:** [Drug-Induced AKI: Mechanisms and Clinical Management](https://urinenephrology.org/student-resources/aki/drug-induced-aki-student-handout.html)


---

[Website version](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html) · Markdown synchronized October 3, 2026.